Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant.

about

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant.

Item

http://www.wikidata.org/entity/Q40955026

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Successful Treatment of Richte ...... opoietic Stem Cell Transplant.

@en

type

Item

label

Successful Treatment of Richte ...... opoietic Stem Cell Transplant.

@en

prefLabel

Successful Treatment of Richte ...... opoietic Stem Cell Transplant.

@en

P1476

Successful Treatment of Richte ...... opoietic Stem Cell Transplant.

@en

P2093

Amol Takalkar

http://www.w3.org/2001/XMLSchema#string

Cheri Leary

http://www.w3.org/2001/XMLSchema#string

Glenn M Mills

http://www.w3.org/2001/XMLSchema#string

James Coltelingam

http://www.w3.org/2001/XMLSchema#string

Nebu Koshy

http://www.w3.org/2001/XMLSchema#string

Richard Mansour

http://www.w3.org/2001/XMLSchema#string

Samip Master

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Spatial variability in tree regeneration after wildfire delays and dampens future bark beetle outbreaks.

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.

Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

P304

534-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1159/000477338

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28690529

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

5498945

http://www.w3.org/2001/XMLSchema#string